Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04957537
Other study ID # RC31/21/0215
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 20, 2021
Est. completion date September 2025

Study information

Verified date July 2023
Source University Hospital, Toulouse
Contact Jérémie PARIENTE, MD PhD
Phone 0561777686
Email pariente.j@chu-toulouse.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project aims to measure the effect of a semantic rehabilitation protocol for patients with primary progressive semantic aphasia and using the SCED methodology.


Description:

The damage on the semantic system is at the heart of the clinical picture of semantic primary progressive aphasia (PPA), a neuro-evolutionary pathology. In other words, patients gradually lose access to concepts, general knowledge, word memory and meaning. In the absence of effective pharmacological treatment to reduce the symptoms evoked by patients and improve their quality of life, the arguments in favour of speech and language therapy are multiplying. Numerous lexico-semantic multimodal indication therapies have been described in scientific studies. The most studied is semantic rehabilitation through the analysis of semantic features, which has shown its effectiveness in the context of vascular and post-traumatic aphasia. However, there are only few studies and applications in neuro-evolutionary pathologies such as semantic PPA and those studies are complicated by methodological biases. It has been shown that relearned knowledge is more likely to be retained and transferred to everyday life (generalisation) if the material used is specific to the needs of each individual. Given the heterogeneity of clinical profiles in neuro-evolving pathologies and the inter-individual variability, the personalised approach should be favoured. To evaluate the effect of semantic therapy in patients with semantic PPA, this study therefore proposes to use the SCED (Single Case Experimental Design) methodology. In addition to allowing an individual analysis, this methodology has the advantage of corresponding to a high level of evidence due to the acquisition of repeated measures and the randomisation of the introduction of the treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date September 2025
Est. primary completion date September 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Have a diagnosis of primary progressive semantic aphasia according to the criteria of Gorno-Tempini et al (2011) (Appendix A) - Being in the mild to moderate stage of dementia (MMSE score between 10 and 28) (Crum et al., 1993; Derouesné et al., 1999) - Common French - Being affiliated to a social security scheme - Being over the age of 18 years old Exclusion Criteria: - Have significant uncorrected visual and/or hearing impairment - Have a history of brain injuries, major head trauma - Have untreated psychiatric disorders - Have significant motor and/or comprehension problems that make it impossible to take part in the study - Chronical use of drugs and/or alcohol - Under guardians or curators - Severe depression (Beck's depression scale score > 9) (Beck & al., 1961)

Study Design


Intervention

Behavioral:
semantic therapy and semantic re-education
Patients will be followed over two periods "Phase A (randomized, 6 to 8 weeks) - Phase B (5 weeks)". Phase A : Baseline Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 to 8 weeks (i.e. 18 to 24 sessions) depending on the randomisation, at the rate of 3 speech therapy sessions of 45 minutes per week. Phase B : Semantic re-education The sessions will consist of training based on the analysis of semantic traits (Coustaut, 2019). This phase will last 5 weeks (i.e. 15 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week. In accordance with the application of the SCED methodology, repeated measurements will be carried out every second session during phases A and B. They will consist of proposing the oral naming task (lasting 10 minutes).

Locations

Country Name City State
France CHU Toulouse Toulouse

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Performance in speaking To evaluate speaking accuracy, the study team will assess the number of correct items recovered by the patient when performing a specific naming task before the rehabilitation.
The naming task is a selection of 80 items developped by Coustaut in 2019 in its MetaLex protocol.
Baseline (before phase A)
Primary Performance in speaking To evaluate speaking response time, the study team will assess the rate at which items are recovered by the patient when performing a specific naming task before the rehabilitation.
The naming task is a selection of 80 items developped by Coustaut in 2019 in its MetaLex protocol.
Baseline (before phase A)
Primary Performance in speaking To evaluate speaking accuracy, the study team will assess the number of correct items repeated by the patient when performing a specific naming task after the rehabilitation.
The naming task is a selection of 80 items developped by Coustaut in 2019 in its MetaLex protocol.
immediately after the intervention (after phase B)
Primary Performance in speaking To evaluate speaking response time, the study team will assess the rate at which items are recovered by the patient when performing a specific naming task after rehabilitation.
The naming task is a selection of 80 items developped by Coustaut in 2019 in its MetaLex protocol.
immediately after the intervention (after phase B)
Secondary Maintenance of the performance in speaking Number of correct items recovered by the patient when performing a specific naming task 1 month after the end of the intervention.
The naming task is a selection of 80 items developped by Coustaut in 2019 in its MetaLex protocol.
This will be compared to the number of items correctly recovered at the end of the rehabilitation (corresponding to outcome 3 here).
1 month after the end of the intervention (after phase B)
See also
  Status Clinical Trial Phase
Suspended NCT04290988 - Circuitry Assessment and Reinforcement Training Effects on Recovery N/A
Completed NCT04045990 - Network Modulation in Alzheimer's Disease N/A
Recruiting NCT05443633 - Enhancing Language Function in Aphasia N/A
Completed NCT05860647 - Transmagnetic Stimulation Pilot in Primary Progressive Aphasia N/A
Recruiting NCT03887481 - Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA N/A
Completed NCT03728582 - Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy N/A
Completed NCT01465360 - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center N/A
Completed NCT02541097 - Preventing Language Decline in Dementia N/A
Recruiting NCT00537004 - Language in Primary Progressive Aphasia
Recruiting NCT05741853 - Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia N/A
Active, not recruiting NCT05742698 - Nabilone for Agitation in Frontotemporal Dementia Phase 2
Completed NCT02439853 - Communication Bridge Speech Therapy Research Study N/A
Completed NCT01623284 - PiB PET Scanning in Speech and Language Based Dementias Phase 1
Completed NCT04726527 - Clinical Evaluation of Florbetapir in Primary Progressive Aphasia
Completed NCT03076671 - More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease N/A
Completed NCT05537688 - Identification of Graphic Markers of Neurocognitive Disorders (MG)
Completed NCT05525377 - Better Living With Non-memory-led Dementia N/A
Completed NCT02928848 - Transcranial Direct Current Stimulation for Primary Progressive Aphasia N/A
Completed NCT04939818 - Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders
Enrolling by invitation NCT05368350 - Treating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation Early Phase 1